Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

Beyond Air

Status

Terminated

Conditions

COVID-19

SARS-CoV 2

Corona Virus Infection

Respiratory Disease

Nitric Oxide

Pneumonia, Viral

Inhaled Nitric Oxide

Treatments

Device: Nitric Oxide delivered via LungFit™ system

Study type

Interventional

Funder types

Industry

Identifiers

NCT04397692

BAI_COV19_01_US

Details and patient eligibility

About

The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

Full description

Nitric Oxide (NO) is a small endogenously produced molecule recognized to play a critical role in the function of several body systems including the vasodilatation of smooth muscle, neurotransmission, regulation of wound healing and inhibition of pathogens. In-vitro studies have shown that NO inhibits the replication cycle of the severe acute respiratory syndrome coronavirus (SARS CoV) in vitro. The suggested mechanisms of actions of NO on SARS are an effect on the fusion between the S protein and its cognate receptor, ACE2, and reduction in viral RNA production in the early steps of viral replication. The primary aim of this feasibility study is to investigate the safety of intermittent NO, delivered via inhalation, in hospitalized patients with COVID-19. The primary endpoint in the study will be time to deterioration of respiratory symptoms determined by escalation to either non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), or intubation.

Enrollment

4 patients

Sex

All

Ages

22 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Enrollment within 24 hours of hospital admission of patients diagnosed with COVID-19
Patients with oxygen saturation less than 93 % on room air
Shortness of breath, with symptom onset within the previous 8 days.
Female subjects of childbearing potential should take adequate measures to avoid pregnancy
Signed informed consent by the subject

Exclusion criteria

Patients who are treated with or require high flow nasal cannula, CPAP, intubation, mechanical ventilation, or tracheostomy
Diagnosis of acute respiratory distress syndrome
Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart disease, left ventricular dysfunction or myocardial damage, severe pulmonary hypertension and/or unstable hypertension
Patients receiving drugs that have contraindications with NO.
Breastfeeding or pregnancy as evidenced by a positive pregnancy test.
Patients with active pulmonary malignancy or lung transplant
Patients with a history of frequent epistaxis or significant hemoptysis